Fetoscopic Endoluminal Tracheal Occlusion

🩺 Protocol Summary

This is a single site pilot trial to study the feasibility of Fetoscopic Endoluminal Tracheal Occlusion (FETO) therapy in the most severe group of fetuses with congenital diaphragmatic hernia (CDH) at Midwest Fetal Care Center, a collaboration between Allina Health and Children's Minnesota. This procedure aims to increase fetal lung volume before birth and improve survival after birth. This study will enroll 10 pregnant people and their baby who meet study criteria.

Primary Research Facility: Midwest Fetal Care Center (Minneapolis, Minnesota)

Review these 3 basic logistical and protocol criteria extracted from the public NIH record. (This is a preliminary logistical checklist, not an official clinical eligibility determination).

Diagnosed with, undergoing evaluation for, or seeking treatment related to Hernia, DIaphragmatic, Congenital?

🔍 Study Population / Focus Area (Source: Protocol Primary Condition)

Aged 18 Years or older? • (Protocol specifies female participants only)

🔍 Protocol Specified Minimum Age: 18 Years

Able to attend required clinic visits at Midwest Fetal Care Center (Minneapolis, Minnesota)?

🔍 Logistical Requirement: Site at Midwest Fetal Care Center

📍 Primary Site Map

Site: Midwest Fetal Care Center — Minneapolis, Minnesota

💰 Clinical Trial Costs & Insurance Coverage

Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.

💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.